Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 4 Issue 2, February 2023

Identifying master kinases in cancer with integrative multi-omics

A kinase–substrate–phosphosite network interactome identifies master kinases specific for glioblastoma subtypes, as potential therapeutic targets.

See Migliozzi et al.

Image: Ella Maru Studio. Cover design: Allen Beattie


Top of page ⤴

News & Views

  • Overall survival for children with rare, relapsed, metastatic and/or refractory cancers has remained unacceptably low over the past four decades. A new precision oncology study introduces an integrative germline and somatic sequencing approach that could breach this impasse to advance cures for children with cancer.

    • Ammar S. Naqvi
    • Jo Lynne Rokita
    News & Views
  • Developing approaches to identify patients who may benefit from specific treatments is an important area of research. A study now defines an HDAC6 score to predict the response of patients with breast cancer to the HDAC6 inhibitor ricolinostat and characterizes its anti-tumor effects with preclinical mechanistic work and a phase 1b clinical trial.

    • Joschka Hey
    • Maria Llamazares Prada
    • Christoph Plass
    News & Views
Top of page ⤴

Research Briefings

  • Using an unbiased algorithm based on kinase–phosphorylation site interactions that is applicable to any proteomic dataset, we identified and experimentally validated two protein kinases (PKCδ and DNA-PKcs) as the master kinases that drive two functional subtypes of glioblastoma multiforme and are potential therapeutic targets of other cancer subtypes.

    Research Briefing
  • Somatic mutations in cancer genomes are caused by multiple mutational processes, each generating characteristic mutational signatures. Our systematic mutational signature analysis of single base substitutions and small insertions and deletions in pediatric cancers indicates that the contribution of signatures of homologous recombination repair defect is limited and identifies a leukemia-specific signature.

    Research Briefing
  • Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of mortality worldwide. Integrative analysis of the genome, transcriptome and proteome of PDAC tissues, also known as proteogenomic analysis, provides insight into the biology of this cancer and is a resource for therapeutic discovery.

    Research Briefing
Top of page ⤴


  • In this review article, Christ and colleagues discuss the recent developments in antibody-based cancer therapies.

    • Sacha Zinn
    • Rodrigo Vazquez-Lombardi
    • Daniel Christ
    Review Article
Top of page ⤴


Top of page ⤴


Quick links